Aurum Biosciences

Glasgow, United Kingdom Founded: 2015 • Age: 11 yrs
Novel oxygen carriers and MRI software for stroke are developed.
Request Access

About Aurum Biosciences

Aurum Biosciences is a company based in Glasgow (United Kingdom) founded in 2015.. Aurum Biosciences has raised $6.3 million across 3 funding rounds from investors including Scottish Enterprise, Infinion BioPharma and InnoScot. The company has 6 employees as of March 31, 2022. Aurum Biosciences offers products and services including ABL-101 and ABL-101 Platform. Aurum Biosciences operates in a competitive market with competitors including Basking Biosciences, Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma and ZZ Biotech, among others.

  • Headquarter Glasgow, United Kingdom
  • Employees 6 as on 31 Mar, 2022
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Aurum Biosciences Limited
  • Date of Incorporation 01 Nov, 2010
  • Jurisdiction GLASGOW, SCOTLAND
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6.3 M (USD)

    in 3 rounds

  • Latest Funding Round
    $926.33 K (USD), Series A

    Jan 31, 2024

  • Investors
  • Employee Count
    6

    as on Mar 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Aurum Biosciences

Aurum Biosciences offers a comprehensive portfolio of products and services, including ABL-101 and ABL-101 Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Injectable for oxygen delivery in stroke and spinal injury treatment

Platform for therapeutics and diagnostics in inflammation and oncology

People of Aurum Biosciences
Headcount 1-10
Employee Profiles 3
Board Members and Advisors 2
Employee Profiles
People
David Brennan
CEO
People
Graeme Deuchar
R&D Director
People
Govind Chavada
Executive Director

Unlock access to complete

Board Members and Advisors
people
Graham Watson
Chairperson
people
Celestine Santosh
Scientific Advisor

Unlock access to complete

Funding Insights of Aurum Biosciences

Aurum Biosciences has successfully raised a total of $6.3M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $926.33 thousand completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $926,326
  • First Round

    (01 Sep 2015)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2024 Amount Series A - Aurum Biosciences Valuation InnoScot
Oct, 2020 Amount Seed - Aurum Biosciences Valuation Infinion BioPharma , Scottish Investment Bank
Sep, 2015 Amount Seed - Aurum Biosciences Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Aurum Biosciences

Aurum Biosciences has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Scottish Enterprise, Infinion BioPharma and InnoScot. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Early-stage Scottish companies are supported with investment and expertise.
Founded Year Domain Location
Supports healthcare innovation by assessing ideas, protecting IP, and facilitating commercial deals.
Founded Year Domain Location
Business development and leadership training programs are offered to companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Aurum Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Aurum Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Aurum Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Aurum Biosciences

Aurum Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Basking Biosciences, Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma and ZZ Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for ischemic stroke treatment are developed.
domain founded_year HQ Location
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
domain founded_year HQ Location
Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury.
domain founded_year HQ Location
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
domain founded_year HQ Location
Genetically engineered proteins for stroke and brain disorders are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Aurum Biosciences

Frequently Asked Questions about Aurum Biosciences

When was Aurum Biosciences founded?

Aurum Biosciences was founded in 2015.

Where is Aurum Biosciences located?

Aurum Biosciences is headquartered in Glasgow, United Kingdom. It is registered at Glasgow, Scotland, United Kingdom.

Is Aurum Biosciences a funded company?

Aurum Biosciences is a funded company, having raised a total of $6.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $4.5M, raised on Sep 01, 2015.

How many employees does Aurum Biosciences have?

As of Mar 31, 2022, the latest employee count at Aurum Biosciences is 6.

What does Aurum Biosciences do?

Aurum Biosciences was founded in 2015 in Glasgow, United Kingdom, as a biopharmaceutical company. Novel perfluorocarbon-based oxygen carriers, known as Oxycyte, are combined with proprietary software and MRI imaging to form the Glasgow Oxygen Level Dependent (GOLD) technology. This is advanced through preclinical development and clinical studies for acute ischaemic stroke, serving as both a diagnostic tool and therapeutic option, with potential follow-on indications.

Who are the top competitors of Aurum Biosciences?

Aurum Biosciences's top competitors include Acticor Biotech, Remedy Pharmaceuticals and Basking Biosciences.

What products or services does Aurum Biosciences offer?

Aurum Biosciences offers ABL-101 and ABL-101 Platform.

Who are Aurum Biosciences's investors?

Aurum Biosciences has 8 investors. Key investors include Scottish Enterprise, Infinion BioPharma, InnoScot, TRICAPITAL Angels, and Celestine Santosh.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available